USANA Health Sciences (NYSE: USNA) and MediWound (NASDAQ:MDWD) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.
This is a breakdown of current recommendations and price targets for USANA Health Sciences and MediWound, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|USANA Health Sciences||0||1||1||0||2.50|
Insider & Institutional Ownership
48.3% of USANA Health Sciences shares are held by institutional investors. Comparatively, 32.9% of MediWound shares are held by institutional investors. 48.0% of USANA Health Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
This table compares USANA Health Sciences and MediWound’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|USANA Health Sciences||5.97%||27.08%||19.75%|
Volatility and Risk
USANA Health Sciences has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500. Comparatively, MediWound has a beta of -0.19, suggesting that its share price is 119% less volatile than the S&P 500.
Valuation and Earnings
This table compares USANA Health Sciences and MediWound’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|USANA Health Sciences||$1.05 billion||2.26||$62.53 million||$4.06||24.22|
|MediWound||$2.50 million||55.18||-$22.14 million||($0.62)||-8.23|
USANA Health Sciences has higher revenue and earnings than MediWound. MediWound is trading at a lower price-to-earnings ratio than USANA Health Sciences, indicating that it is currently the more affordable of the two stocks.
USANA Health Sciences beats MediWound on 10 of the 14 factors compared between the two stocks.
USANA Health Sciences Company Profile
USANA Health Sciences, Inc. develops and manufactures science-based nutritional and personal care products. The Company operates as a direct selling company in two geographic regions: Americas and Europe, and Asia Pacific, which includes three sub-regions: Southeast Asia Pacific, Greater China and North Asia. Its product lines include USANA Nutritionals Essentials, Optimizers, Foods, Sense-beautiful science and All Other. Its USANA Nutritionals Essentials product line includes vitamin and mineral supplements that provide a foundation of total body nutrition for every age group beginning with children of approximately one year. Its Optimizers product line consists of targeted supplements designed to meet individual health and nutritional needs. Its Sense-beautiful science product line includes science-based, personal care products that support skin and hair by providing topical nourishment, moisturization and protection.
MediWound Company Profile
MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina. The company also develops EscharEx, which is in Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.